MedTwenty

NHS England directly awards PERFORMS £1.4m for breast and lung screening training

NHS England has awarded PERFORMS Assessment Ltd a £1,428,891 contract, excluding VAT, for national test and training services supporting the breast and lung cancer screening programmes, a notice shows.

MedTwenty Editorial··4 min read

Share
Medical imaging and healthcare finance. Stacks of coins and a notebook with a pen.
Medical imaging and healthcare finance. Stacks of coins and a notebook with a pen.

NHS England has awarded a contract worth £1,428,891 excluding VAT to PERFORMS Assessment Ltd for the national test and training services that support the NHS Breast Screening Programme and the NHS Lung Cancer Screening Programme, according to a notice published on Find a Tender on 4 November 2026.

The notice records the procedure as a direct award. NHS England awarded the contract on 27 October 2026, and the contract period runs from 13 November 2026 to 31 October 2027. The status of the award itself is listed as pending, while the notice status is shown as complete.

The notice is an award update and contract update. It lists a single award under the title Breast and Lung Screening - Test and Training Provision, with PERFORMS Assessment Ltd as the only named supplier.

What the services cover

According to the notice, the services provide independent quality assurance, assessment, benchmarking and learning tools. These are intended to help ensure that screening staff maintain the knowledge and skills needed to carry out screening safely and consistently.

The notice says the investment will allow the existing services to continue while a targeted improvement programme is put in place. The programme is aimed at strengthening security, resilience, assurance, user experience and long-term sustainability.

The buyer describes the approach as building on established national platforms that are already embedded in both screening programmes. According to the notice, this avoids the cost, risk and disruption associated with developing replacement systems.

The notice does not break down how the £1,428,891 is split between continued delivery of the existing services and the improvement programme. It also does not state whether the contract can be extended beyond 31 October 2027, or whether other suppliers were considered.

The award is recorded as pending in the notice, and the contract dates above are those given there.

Why it matters

The notice shows NHS England choosing to keep established national platforms in place and fund improvements, rather than commissioning replacements. That could signal that incumbent screening-support tools are hard to displace, which is relevant to suppliers considering entry into screening quality assurance. For NHS buyers, it is an example of a direct award justified by cost, risk and disruption, though the notice gives no further detail on that choice.

Source: Find a Tender